AstraZeneca Coronavirus Vaccine Candidate Shows Up to 90% Efficacy in Interim AnalysisThe Motley Fool • 11/23/20
Oxford University's COVID-19 vaccine shows high efficacy, and is cheaper to make and easier to storeTechCrunch • 11/23/20
Oxford COVID-19 vaccine: not as effective, but better than other vaccines in two big waysFast Company • 11/23/20
Oxford Biomedica notes AstraZeneca's AZD1222 met primary efficacy endpoint in preventing COVID-19GlobeNewsWire • 11/23/20
Oxford and AstraZeneca's COVID-19 vaccine is considerably cheaper and easier to distribute than either Pfizer's or Moderna's. Here's why.Business Insider • 11/23/20
AstraZeneca-Oxford Vaccine Up To 90% Effective At Preventing Covid-19, Early Results ShowForbes • 11/23/20
AstraZeneca slides after announcing its COVID-19 vaccine candidate is 70% effectiveBusiness Insider • 11/23/20
AstraZeneca, Oxford Covid-19 vaccine can be up to 90% effective, late-stage trials showMarket Watch • 11/23/20
Bill Gates Says AstraZeneca, Johnson & Johnson, Novavax COVID-19 Vaccines All Likely To Prove 'Very Efficacious And Safe' By FebruaryBenzinga • 11/23/20
AstraZeneca and Oxford University announced a 3rd working COVID-19 vaccine, which they say is 70% effectiveBusiness Insider • 11/23/20
AstraZeneca study finds its COVID-19 vaccine effective, with one regimen showing 90% efficacyMarket Watch • 11/23/20
AstraZeneca releases positive Phase 2 COVID-19 vaccine data, says Phase 3 data available by ChristmasFox Business • 11/19/20
Oxford trial chief says its Covid vaccine could still be ready at a similar time to othersCNBC • 11/19/20
AstraZeneca gains after its COVID-19 vaccine produced immune response in elderly, Oxford study showsBusiness Insider • 11/19/20
A Virologist Explains: mRNA Coronavirus Vaccines And What Investors Should KnowThe Motley Fool • 11/19/20